Drugs / Recombinant new coronavirus vaccine (CHO cell)
Recombinant new coronavirus vaccine (CHO cell)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04550351 | Aug → Dec 2020 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05107375 | Sep 2021 → Mar 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05890521 | Apr → Jun 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05089045 | Aug → Sep 2021 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant new coronavirus vaccine (CHO cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05089045 ↗ |
| Known as | Recombinant new coronavirus vaccine (CHO cells) | “Recombinant new coronavirus vaccine (CHO cells)” NCT05089045 ↗ |
| Known as | Recombinant Novel Coronavirus Vaccine | “Recombinant Novel Coronavirus vaccine (CHO cells)” NCT05089045 ↗ |
| Known as | Recombinant Novel Coronavirus vaccine (CHO cells) | “Recombinant Novel Coronavirus vaccine (CHO cells)” NCT05089045 ↗ |
| Modality | Vaccine | “Recombinant New Coronavirus Vaccine” NCT04550351 ↗ |
| Route | Intramuscular | “Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).” NCT04550351 ↗ |